MEDS News

Small-cap stocks are kicking off October with a mix of milestones, putting Nexalin Technology (NASDAQ:NXL), Kraig Biocraft Laboratories (OTCQB:KBLB), Veea (NASDAQ:VEEA), DataMeds AI (NASDAQ:MEDS), Generation Income Properties (NASDAQ:GIPR),  and American Battery Technology Company (NASDAQ:ABAT) firmly on the radar.

DataMeds AI (NASDAQ:MEDS) is entering October with a fresh revenue milestone that puts the company's rapidly expanding healthcare platform squarely in focus. Corexa Pharmacy, a division of wholly owned Corexa Health, generated preliminary, unaudited September 2026 revenue of more than $1 million, representing an increase of more than 66% from July 2026, according to the company. The update comes only months after DataMeds changed its corporate name from Wellgistics Health and its Nasdaq ticker from WGRX to MEDS, while repositioning the business around pharmacy infrastructure, health technology, artificial intelligence and pharmaceutical-adjacent services.

Kodiak Sciences (NASDAQ:KOD), NeOnc Technologies Holdings (NASDAQ:NTHI), KNOREX (NYSEAMERICAN:KNRX), DataMeds AI (NASDAQ:MEDS), Accuray (NASDAQ:ARAY) and AMC Entertainment (NYSE:AMC) are each approaching important milestones that could reshape how investors view their pipelines, platforms and near-term prospects.

Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million. Geovax Labs (NASDAQ:GOVX) stock roseread more...

Major U.S. indices ended Wednesday in the red as the Federal Reserve raised interest rates by 0.25%, marking the first increase since 2023. The Dow Jones Industrial Average fell 1.2% to 51,461.90, while the S&Pread more...

Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved upwards byread more...

DataMEDS AI shares jumped 8.02% in overnight session Tuesday after the company completed its $1.5 million Helomics acquisition.read more...

Major U.S. indices closed lower on Tuesday, with the Dow Jones Industrial Average falling 0.63% to 52,093.11.read more...

DataMEDS AI (NASDAQ:MEDS) just made a sharp turn toward one of healthcare’s biggest opportunities: artificial intelligence-powered cancer diagnostics and precision oncology, with the completion of its acquisition of Helomics Corporation from Axe Compute (NASDAQ:AGPU), acquiring a CLIA/CAP-certified clinical laboratory, the Predictive Oncology CRO central-lab business and $1.5 million in cash. The transaction has a total purchase value of $1.5 million, consisting of DataMEDS common shares and an acquisition note.